Gavin J Kilpatrick

List of Publications by Year in Descending Order

73 papers	5,766 citations	38 h-index	75 g-index
75 ext. papers	6,143 ext. citations	6.1 avg, IF	5.08 L-index

#	Paper	IF	Citations
73	Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent. *Frontiers in Pharmacology*, **2021**, 12, 690875	5.6	9
72	Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures. *Frontiers in Immunology*, **2020**, 11, 605170	8.4	38
71	A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. *Anesthesia and Analgesia*, **2012**, 115, 274-83	3.9	102
70	A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. *Anesthesia and Analgesia*, **2012**, 115, 284-96	3.9	71
69	CNS 7056: a novel ultra-short-acting Benzodiazepine. *Anesthesiology*, **2007**, 107, 60-6	4.3	110
68	Drug development in anaesthesia: industrial perspective. *Current Opinion in Anaesthesiology*, **2006**, 19, 385-9	2.9	12
67	Morphine-6-glucuronide: actions and mechanisms. *Medicinal Research Reviews*, **2005**, 25, 521-44	14.4	107
66	Molecular biology of the CRH receptors-- in the mood. *Peptides*, **2001**, 22, 753-60	3.8	100
65	A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 4938-43	11.5	260
64	Evidence for the abundant expression of arginine 185 containing human CRF(2alpha) receptors and the role of position 185 for receptor-ligand selectivity. *Neuropharmacology*, **2000**, 39, 1368-76	5.5	26
63	Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171--PET studies in rhesus monkey. *Neuropharmacology*, **2000**, 39, 664-70	5.5	61
62	The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: generation of chimeric receptors with a novel ligand-selective profile. *Journal of Neurochemistry*, **1999**, 73, 821-9	6	39
61	5-HT(3) receptor antagonists. *Expert Opinion on Investigational Drugs*, **1999**, 8, 2183-2188	5.9	5
60	Urocortin: slower dissociation than corticotropin releasing factor from the CRF binding protein. *European Journal of Pharmacology*, **1999**, 376, 321-4	5.3	5
59	7TM receptors: the splicing on the cake. *Trends in Pharmacological Sciences*, **1999**, 20, 294-301	13.2	96
58	Human CRF2 alpha and beta splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay. *Neuropharmacology*, **1999**, 38, 441-8	5.5	47
57	Pharmacological characterisation of the recombinant human CRF binding protein using a simple assay. *Journal of Neuroscience Methods*, **1998**, 80, 99-105	3	10

56	Urocortin, a novel neuropeptide with anxiogenic-like properties. *NeuroReport*, **1997**, 8, 1697-701	1.7	151
55	Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 14854-8	11.5	309
54	Labelling of CRF1 and CRF2 receptors using the novel radioligand, [3H]-urocortin. *Neuropharmacology*, **1997**, 36, 1439-46	5.5	40
53	A new functional isoform of the human CRF2 receptor for corticotropin-releasing factor. *Biochimica Et Biophysica Acta Gene Regulatory Mechanisms*, **1997**, 1352, 129-32		85
52	Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. *Oncology*, **1996**, 53 Suppl 1, 102-9	3.6	29
51	5-HT3 and 5-HT4 receptors in terminal regions of the mesolimbic system. *Behavioural Brain Research*, **1996**, 73, 11-3	3.4	25
50	GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. *Regulatory Peptides*, **1996**, 65, 45-53		128
49	Characterisation of the specific binding of the histamine H3 receptor antagonist radioligand [3H]GR168320. *European Journal of Pharmacology*, **1996**, 311, 305-10	5.3	13
48	Novel 6-substituted 2-aminotetralins with potent and selective affinity for the dopamine D3 receptor. *Bioorganic and Medicinal Chemistry Letters*, **1996**, 6, 403-408	2.9	23
47	A novel series of arylpiperazines with high affinity and selectivity for the dopamine D3 receptor. *Bioorganic and Medicinal Chemistry Letters*, **1995**, 5, 219-222	2.9	52
46	A pharmacological comparison of [3H]-granisetron binding sites in brain and peripheral tissues of the mouse. *Naunyn-Schmiedebergs Archives of Pharmacology*, **1995**, 351, 221-8	3.4	8
45	The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. *British Journal of Pharmacology*, **1995**, 116, 3158-63	8.6	96
44	Cloning and characterisation of the human 5-HT5A serotonin receptor. *FEBS Letters*, **1994**, 355, 242-6	3.8	101
43	Thioperamide, the selective histamine H3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. *European Journal of Pharmacology*, **1994**, 259, 107-14	5.3	82
42	Characterization of [3H]meta-chlorophenylbiguanide binding to 5-HT3 receptors in N1E-115 neuroblastoma cells. *European Journal of Pharmacology*, **1993**, 243, 7-11	5.3	28
41	Labelling of 5-HT3 receptor recognition sites in the rat brain using the agonist radioligand [3H]meta-chlorophenylbiguanide. *European Journal of Pharmacology*, **1993**, 243, 13-8	5.3	35
40	Histamine H3 receptor-mediated modulation of water consumption in the rat. *European Journal of Pharmacology*, **1993**, 232, 99-103	5.3	53
39	Development of a radioligand binding assay for 5-HT4 receptors in guinea-pig and rat brain. *British Journal of Pharmacology*, **1993**, 109, 618-24	8.6	245

38	Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse. *Psychopharmacology*, **1993**, 112, S68-75	4.7	36
37	Inter-species variants of the 5-HT3 receptor. *Biochemical Society Transactions*, **1992**, 20, 118-21	5.1	31
36	Characterization of histamine-H3 receptors controlling non-adrenergic non-cholinergic contractions of the guinea-pig isolated ileum. *British Journal of Pharmacology*, **1992**, 105, 667-74	8.6	53
35	Histamine H3 receptors modulate the release of [3H]-acetylcholine from slices of rat entorhinal cortex: evidence for the possible existence of H3 receptor subtypes. *British Journal of Pharmacology*, **1992**, 107, 919-23	8.6	199
34	A post-synaptic depressant modulatory action of 5-hydroxytryptamine on excitatory amino acid responses in rat entorhinal cortex in vitro. *Neuropharmacology*, **1992**, 31, 531-9	5.5	23
33	In vivo occupancy of histamine H3 receptors by thioperamide and (R)-alpha-methylhistamine measured using histamine turnover and an ex vivo labeling technique. *Biochemical Pharmacology*, **1992**, 44, 1261-7	6	36
32	The distribution of 5-HT3 recognition sites in the marmoset brain. *European Journal of Pharmacology*, **1992**, 215, 63-7	5.3	20
31	GR-68755 Hydrochloride. *Drugs of the Future*, **1992**, 17, 660	2.3	12
30	The pharmacological characterization of 5-HT3 receptor binding sites in rabbit ileum: Comparison with those in rat ileum and rat brain. *Neurochemistry International*, **1991**, 19, 389-396	4.4	31
29	[3H] GR67330, a very high affinity ligand for 5-HT3 receptors. *Naunyn-Schmiedebergs Archives of Pharmacology*, **1990**, 342, 22-30	3.4	32
28	Characterization of 5-HT3 receptors in intact N1E-115 neuroblastoma cells. *European Journal of Pharmacology*, **1990**, 189, 223-7		39
27	Target size of 5-HT3 receptors in N1E-115 neuroblastoma cells and rat brain. *European Journal of Pharmacology*, **1990**, 189, 229-32		8
26	5-HT3 receptors. *Medicinal Research Reviews*, **1990**, 10, 441-75	14.4	168
25	Identification and distribution of 5-HT3 recognition sites within the human brainstem. *Neuroscience Letters*, **1990**, 111, 80-6	3.3	38
24	Consensus meeting agrees distribution of 5-HT3 receptors in mammalian hindbrain. *Trends in Pharmacological Sciences*, **1990**, 11, 135-7	13.2	104
23	1-(m-chlorophenyl)-biguanide, a potent high affinity 5-HT3 receptor agonist. *European Journal of Pharmacology*, **1990**, 182, 193-7	5.3	153
22	The pharmacological characterization of 5-HT3 receptors in three isolated preparations derived from guinea-pig tissues. *British Journal of Pharmacology*, **1990**, 101, 591-8	8.6	98
21	Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. *European Journal of Pharmacology*, **1989**, 159, 157-64	5.3	201

20	5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. *British Journal of Pharmacology*, **1989**, 97, 247-55	8.6	189
19	Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. *Neuroscience Letters*, **1989**, 101, 305-10	3.3	54
18	Interaction of neuroleptic drugs with rat striatal D-1 and D-2 dopamine receptors: a quantitative structure□affinity relationship study. *European Journal of Medicinal Chemistry*, **1988**, 23, 173-182	6.8	27
17	The distribution of specific binding of the 5-HT3 receptor ligand [3H]GR65630 in rat brain using quantitative autoradiography. *Neuroscience Letters*, **1988**, 94, 156-60	3.3	111
16	The influence of aromatic substituents on the binding of substituted benzamides to dopamine D-2 receptors: congruent QSAR and MEP analyses. *Journal of Pharmacy and Pharmacology*, **1987**, 39, 767-8	4.8	5
15	Effects of continuous administration for 12 months of amine-depleting drugs and chlorpromazine on striatal dopamine function in the rat. *Neuropharmacology*, **1987**, 26, 1061-9	5.5	3
14	Do thermodynamic studies provide information on both the binding to and the activation of dopaminergic and other receptors?. *Biochemical Pharmacology*, **1987**, 36, 4041-6	6	53
13	Pharmacological analysis of 125I-Bolton and Hunter labelled eledoisin binding sites in rat spinal cord by quantitative autoradiography. *Neuroscience Letters*, **1987**, 78, 12-6	3.3	16
12	Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. *Nature*, **1987**, 330, 746-8	50.4	814
11	[3H]SCH 23390 identifies D-1 binding sites in rat striatum and other brain areas. *Journal of Pharmacy and Pharmacology*, **1986**, 38, 907-12	4.8	27
10	[125I]Spiperone is not a useful ligand for studying the CHAPS solubilized dopamine D-2 receptor from rat striatum. *Journal of Pharmacy and Pharmacology*, **1986**, 38, 406-8	4.8	5
9	Specific [3H]piflutixol binding to CHAPS-solubilised rat striatal preparations involves dopamine D-2 but not D-1 binding sites. *Journal of Neurochemistry*, **1986**, 46, 413-21	6	10
8	Properties of rat striatal D-2 dopamine receptors solubilized with the zwitterionic detergent CHAPS. *Journal of Pharmacy and Pharmacology*, **1985**, 37, 320-8	4.8	15
7	Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs. *Journal of Neural Transmission*, **1985**, 62, 249-66	4.3	24
6	Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. *Biochemical Pharmacology*, **1985**, 34, 2755-63	6	86
5	Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat. *Psychopharmacology*, **1984**, 84, 503-11	4.7	56
4	Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats. *Psychopharmacology*, **1984**, 84, 512-9	4.7	68
3	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. *Neuroscience Letters*, **1984**, 50, 85-90	3.3	304

2	The binding of [3H]N-(chloroethyl)-norapomorphine to rat striatal membranes. *European Journal of Pharmacology*, **1984**, 107, 71-8	5.3	1
1	Deep sequencing of B cell receptor repertoires from COVID-19 patients reveals strong convergent immune signatures		11